General Genomics Inc.

Operating

Biotech · Founded 2020

Visit website

Accurately predict your risk of infectious disease (like COVID) and take control

Valuation cap ⓘ

$50.0M

As of May 2021 · from Reg CF Offering (2021) · a SAFE/note conversion ceiling, not a priced valuation

Total raised

$4,074,336

Crowd $27K · Private $4.0M · 3 rounds since 2021

Financials

FY2018–FY2023 (no data for FY2020) · from SEC filings · hover any figure for its source

2018

$219K

−$526K

2019

2020no data

−$149K

2021

$8K

−$245K

2022

$441K

−$607K

2023

RevenueNet income — beside revenue when positive, below the line when a loss

Metric

FY2018

FY2019 reviewed*

FY2021

FY2022 reviewed

FY2023 reviewed

Income statement

Revenue

$219,313

$8,269

$440,579

Cost of goods sold

$23,565

Gross margin

—

89%

—

100%

Net income

-$526,180

-$149,393

-$245,162

-$606,779

Taxes paid

Balance sheet

Cash

$158,806

$58,321

$223,086

$106,008

Accounts receivable

$236,696

$231,908

$371,866

Total assets

$487,534

$364,344

$827,013

$1,336,650

Short-term debt

$17,382

$2,130

$4,300

Long-term debt

$65,829

Total liabilities

$83,211

$2,130

$4,300

Other

Headcount

—

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Valuation caps on SAFE / convertible note rounds

$50.0M

Valuation cap

Reg CF · SAFE · Jan 2021

Dashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.

Fundraising history

Rule 506(b) · Convertible Note · May 2024Open

Raised $2.8MInvestors 21

Rule 506(b) · Equity · Aug 2021Open

Raised $1.3MInvestors 8

Reg CF · SAFE · Jan 2021Closedvia WeFunder

Raised $26.6K / $1.1MInvestors 17Valuation cap $50M

Team

3 people

Aronjol David Rosenthal

President

Warren Dennis Gieck

VP Engineering and Product Development

Caleb Stuart

SVP, General Counsel, and Secretary

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFiled Form C-TR (terminated reporting)

Filed 2 of 6 annual reports (FY2020–FY2025)

21 investors

holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

Form DJan 27, 20260001834175-26-000002
EDGAR
Form DJan 27, 20260001834175-26-000001
EDGAR
Form C-TRDec 16, 20250001834175-25-000004
EDGAR
Form C-ARApr 30, 20240001834175-24-000001
EDGAR
Form C-ARMay 2, 20230001834175-23-000001
EDGAR
Form C/AApr 21, 20210001670254-21-000511
EDGAR
Form CDec 10, 20200001670254-20-001130
EDGAR

Source: ManualCIK 0001834175

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.